248 related articles for article (PubMed ID: 24054128)
1. Dickkopf-1 is a key regulator of myeloma bone disease: opportunities and challenges for therapeutic intervention.
Zhou F; Meng S; Song H; Claret FX
Blood Rev; 2013 Nov; 27(6):261-7. PubMed ID: 24054128
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
Yaccoby S; Ling W; Zhan F; Walker R; Barlogie B; Shaughnessy JD
Blood; 2007 Mar; 109(5):2106-11. PubMed ID: 17068150
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
[TBL] [Abstract][Full Text] [Related]
4. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
Tian E; Zhan F; Walker R; Rasmussen E; Ma Y; Barlogie B; Shaughnessy JD
N Engl J Med; 2003 Dec; 349(26):2483-94. PubMed ID: 14695408
[TBL] [Abstract][Full Text] [Related]
5. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.
Eda H; Santo L; Wein MN; Hu DZ; Cirstea DD; Nemani N; Tai YT; Raines SE; Kuhstoss SA; Munshi NC; Kronenberg HM; Raje NS
J Bone Miner Res; 2016 Jun; 31(6):1225-34. PubMed ID: 26763740
[TBL] [Abstract][Full Text] [Related]
7. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.
Colla S; Zhan F; Xiong W; Wu X; Xu H; Stephens O; Yaccoby S; Epstein J; Barlogie B; Shaughnessy JD
Blood; 2007 May; 109(10):4470-7. PubMed ID: 17255354
[TBL] [Abstract][Full Text] [Related]
8. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
Qian J; Zheng Y; Zheng C; Wang L; Qin H; Hong S; Li H; Lu Y; He J; Yang J; Neelapu S; Kwak LW; Hou J; Yi Q
Blood; 2012 Jan; 119(1):161-9. PubMed ID: 22049519
[TBL] [Abstract][Full Text] [Related]
9. Correlations of DKK1 with pathogenesis and prognosis of human multiple myeloma.
Feng Y; Zhang Y; Wei X; Zhang Q
Cancer Biomark; 2019; 24(2):195-201. PubMed ID: 30614800
[TBL] [Abstract][Full Text] [Related]
10. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
Pozzi S; Fulciniti M; Yan H; Vallet S; Eda H; Patel K; Santo L; Cirstea D; Hideshima T; Schirtzinge L; Kuhstoss S; Anderson KC; Munshi N; Scadden D; Kronenberg HM; Raje N
Bone; 2013 Apr; 53(2):487-96. PubMed ID: 23333523
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia with osteolytic Richter's syndrome mimicking myeloma bone disease shows no over-expression of DKK1.
Lazarevic V; Wahlin A; Hultdin M; Zhan F; Shaughnessy J
Leuk Lymphoma; 2006 Sep; 47(9):1987-8. PubMed ID: 17065022
[No Abstract] [Full Text] [Related]
12. Cyclized Oligopeptide Targeting LRP5/6-DKK1 Interaction Reduces the Growth of Tumor Burden in a Multiple Myeloma Mouse Model.
Park BM; Kim EJ; Nam HJ; Zhang D; Bae CH; Kang M; Kim H; Lee W; Bogen B; Lim SK
Yonsei Med J; 2017 May; 58(3):505-513. PubMed ID: 28332354
[TBL] [Abstract][Full Text] [Related]
13. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma.
Xu Y; Guo J; Liu J; Xie Y; Li X; Jiang H; Wang J; Peng Z; Wang J; Wang S; Wan C; Chen L; Zhong Y; Liu B; Liu Z
Oncogene; 2021 Feb; 40(7):1231-1241. PubMed ID: 33420361
[TBL] [Abstract][Full Text] [Related]
15. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.
Fowler JA; Mundy GR; Lwin ST; Edwards CM
Cancer Res; 2012 May; 72(9):2183-9. PubMed ID: 22374979
[TBL] [Abstract][Full Text] [Related]
17. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.
Haaber J; Abildgaard N; Knudsen LM; Dahl IM; Lodahl M; Thomassen M; Kerndrup GB; Rasmussen T
Br J Haematol; 2008 Jan; 140(1):25-35. PubMed ID: 18005268
[TBL] [Abstract][Full Text] [Related]
18. Dickkopf-related protein 1 expression in bone marrow of multiple myeloma patients: correlation with bone disease and plasma cell malignancy type.
Auziņa D; Beinaroviča I; Janicka-Kupra B; Lejniece S; Lejnieks A; Groma V
Exp Oncol; 2020 Dec; 42(4):285-288. PubMed ID: 33355872
[TBL] [Abstract][Full Text] [Related]
19. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
[TBL] [Abstract][Full Text] [Related]
20. [Bone marrow plasma concentrations of Dickkopf1 in patients with multiple myeloma].
Dun XY; Jiang H; Hou J
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 38(5):453-8. PubMed ID: 19830856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]